Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
79.02 USD | -2.40% |
|
-0.33% | -20.52% |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 47.99B | 48.7B | 59.28B | 60.12B | 64.17B | |||||
Total Revenues | 47.99B | 48.7B | 59.28B | 60.12B | 64.17B | |||||
Cost of Goods Sold, Total | 13.42B | 13.24B | 17.21B | 15.92B | 14.7B | |||||
Gross Profit | 34.57B | 35.46B | 42.08B | 44.2B | 49.47B | |||||
Selling General & Admin Expenses, Total | 9.37B | 9.4B | 9.67B | 9.88B | 10.1B | |||||
R&D Expenses | 10.31B | 10.2B | 11.84B | 18.34B | 14.48B | |||||
Other Operating Expenses, Total | 19.68B | 19.61B | 21.51B | 28.23B | 24.58B | |||||
Operating Income | 14.89B | 15.86B | 20.56B | 15.97B | 24.89B | |||||
Interest Expense, Total | -831M | -806M | -962M | -1.15B | -1.27B | |||||
Interest And Investment Income | 59M | 36M | 314M | 365M | 415M | |||||
Net Interest Expenses | -772M | -770M | -648M | -781M | -856M | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Currency Exchange Gains (Loss) | -145M | -297M | -237M | -370M | -227M | |||||
Other Non Operating Income (Expenses) | 126M | 256M | 524M | 420M | 290M | |||||
EBT, Excl. Unusual Items | 14.1B | 15.05B | 20.2B | 15.24B | 24.1B | |||||
Restructuring Charges | -883M | -868M | -666M | -933M | -888M | |||||
Merger & Related Restructuring Charges | -4.75B | -1.7B | - | -11.41B | -3.46B | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 1.34B | 1.94B | -1.42B | 340M | 14M | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Asset Writedown | -90M | -275M | -1.6B | -779M | - | |||||
In Process R&D Expenses | - | - | - | - | - | |||||
Legal Settlements | - | - | - | -573M | - | |||||
Other Unusual Items | -920M | -260M | -75M | - | 170M | |||||
EBT, Incl. Unusual Items | 8.79B | 13.88B | 16.44B | 1.89B | 19.94B | |||||
Income Tax Expense | 1.71B | 1.52B | 1.92B | 1.51B | 2.8B | |||||
Earnings From Continuing Operations | 7.08B | 12.36B | 14.53B | 377M | 17.13B | |||||
Earnings Of Discontinued Operations | - | 704M | - | - | - | |||||
Net Income to Company | 7.08B | 13.06B | 14.53B | 377M | 17.13B | |||||
Minority Interest | -15M | -13M | -7M | -12M | -16M | |||||
Net Income - (IS) | 7.07B | 13.05B | 14.52B | 365M | 17.12B | |||||
Net Income to Common Incl Extra Items | 7.07B | 13.05B | 14.52B | 365M | 17.12B | |||||
Net Income to Common Excl. Extra Items | 7.07B | 12.34B | 14.52B | 365M | 17.12B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 2.79 | 5.16 | 5.73 | 0.14 | 6.76 | |||||
Basic EPS - Continuing Operations | 2.79 | 4.88 | 5.73 | 0.14 | 6.76 | |||||
Basic Weighted Average Shares Outstanding | 2.53B | 2.53B | 2.53B | 2.54B | 2.53B | |||||
Net EPS - Diluted | 2.78 | 5.14 | 5.71 | 0.14 | 6.74 | |||||
Diluted EPS - Continuing Operations | 2.78 | 4.86 | 5.71 | 0.14 | 6.74 | |||||
Diluted Weighted Average Shares Outstanding | 2.54B | 2.54B | 2.54B | 2.55B | 2.54B | |||||
Normalized Basic EPS | 3.48 | 3.71 | 4.98 | 3.75 | 5.94 | |||||
Normalized Diluted EPS | 3.46 | 3.7 | 4.96 | 3.74 | 5.92 | |||||
Dividend Per Share | 2.44 | 2.6 | 2.76 | 2.92 | 3.08 | |||||
Payout Ratio | 87.94 | 50.66 | 48.3 | 2.04K | 45.8 | |||||
American Depositary Receipts Ratio (ADR) | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |||||
Supplemental Items | ||||||||||
EBITDA | 18.24B | 18.98B | 24.35B | 19.71B | 29.13B | |||||
EBITA | 16.79B | 17.49B | 22.65B | 18.02B | 27.28B | |||||
EBIT | 14.89B | 15.86B | 20.56B | 15.97B | 24.89B | |||||
EBITDAR | 18.59B | 19.32B | 24.69B | 20.04B | 29.48B | |||||
Effective Tax Rate - (Ratio) | 19.44 | 10.96 | 11.66 | 80.04 | 14.06 | |||||
Current Domestic Taxes | 1.02B | 61M | 2.32B | 976M | 929M | |||||
Current Foreign Taxes | 1.36B | 1.27B | 1.16B | 2.44B | 3.12B | |||||
Total Current Taxes | 2.38B | 1.33B | 3.49B | 3.41B | 4.05B | |||||
Deferred Domestic Taxes | -628M | 264M | -1.64B | -1.67B | -1.46B | |||||
Deferred Foreign Taxes | -40M | -77M | 71M | -233M | 212M | |||||
Total Deferred Taxes | -668M | 187M | -1.57B | -1.9B | -1.25B | |||||
Normalized Net Income | 8.8B | 9.39B | 12.62B | 9.51B | 15.04B | |||||
Non-Cash Pension Expense | -207M | 17M | -101M | -396M | -509M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 2B | 2B | 2.2B | 2.3B | 2.4B | |||||
Selling and Marketing Expenses | 2B | 2B | 2.2B | 2.3B | 2.4B | |||||
Research And Development Expense From Footnotes | 13.56B | 12.24B | 13.55B | 30.53B | 17.94B | |||||
Net Rental Expense, Total | 346M | 343M | 334M | 339M | 348M | |||||
Imputed Operating Lease Interest Expense | 75.66M | 65M | 77.17M | 91.07M | 94.94M | |||||
Imputed Operating Lease Depreciation | 270M | 278M | 257M | 248M | 253M | |||||
Stock-Based Comp., Other (Total) | 475M | 479M | 541M | 645M | 761M | |||||
Total Stock-Based Compensation | 475M | 479M | 541M | 645M | 761M |
- Stock Market
- Equities
- MRK Stock
- Financials Merck & Co., Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition